Theo Nicolaides, MD

Assistant Professor
Department of Pediatrics
Department of Neurosurgery
+1 415 476-3831

I am a physician scientist in the field of pediatric neuro-oncology. I am currently an Assistant Professor at UCSF and have independent lab space in the Brain Tumor Research Center supported through an NIH SPORE award. I also am Director of the UCSF Brain Tumor Research Center Pre-Clinical (animal research) Core that generates new patient derived xenografts and cell lines from all pediatric brain tumor patients at UCSF and uses these for rationally designed preclinical experiments. My research interests are in identifying and validating therapeutic targets in brain tumors using in vitro and in vivo techniques. My current work focuses on EGFR activation in adult gliomas, and MAP kinase pathway activation in pediatric gliomas, and opportunities created for targeted therapy. We have published data supporting the substantial frequency of BRAFV600E mutations in pediatric astrocytomas, and have demonstrated the pre-clinical efficacy of PLX4032 (a BRAFV600E kinase inhibitor) in xenograft models. This data has led to a multi-center clinical trial using this approach that I chair through the Pacific Pediatric Neuro-Oncology Consortium (PNOC). My lab also performed the biology studies for a recent phase 1 trial conducted by the Pediatric Brain Tumor Consortium testing a MEK inhibitor, selumetinib, in pediatric gliomas. 

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Neurobiology
Research Summary: 
Targeted therapy for brain tumors.
Publications: 

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Cancer cell

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Cancer cell

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DM, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A

Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas.

Journal of neuro-oncology

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Neuro-oncology

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AG, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.

Oncotarget

Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK